Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy.
Idilman
R
R
D000970:Antineoplastic Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006509:Hepatitis B / Q000517:prevention & control*; D006515:Hepatitis B virus / Q000502:physiology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D014775:Virus Activation / Q000187:drug effects
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D019259:Lamivudine